Trials / Completed
CompletedNCT03969888
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222
A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 78 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety, tolerability, and efficacy of ABBV-3067 given alone and in combination with various doses of ABBV-2222 in adults with Cystic Fibrosis who are homozygous for the F508del mutation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABBV-3067 | Tablet taken orally. |
| DRUG | Placebo ABBV-3067 | Tablet taken orally. |
| DRUG | ABBV-2222 | Capsule taken orally. |
| DRUG | Placebo ABBV-2222 | Capsule taken orally. |
Timeline
- Start date
- 2019-12-11
- Primary completion
- 2022-06-09
- Completion
- 2022-06-09
- First posted
- 2019-05-31
- Last updated
- 2023-06-28
- Results posted
- 2023-06-28
Locations
51 sites across 12 countries: United States, Belgium, Canada, Czechia, France, Hungary, Netherlands, New Zealand, Poland, Serbia, Slovakia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03969888. Inclusion in this directory is not an endorsement.